Methylphenidate, cognition, and epilepsy: A 1-month open-label trial.
Adams, Jesse; Alipio-Jocson, Valerie; Inoyama, Katherine; Bartlett, Victoria; Sandhu, Saira; Oso, Jemima; Barry, John J; Loring, David W; Meador, Kimford J.
; 58(12): 2124-2132, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28990169
Pharmacological interventions for apathy in Alzheimer's disease.
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study.
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit.
Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves.